BACKGROUND: In Canada, a pneumococcal conjugate vaccine was licensed in 2001, and in the province of Quebec, a publicly-funded program was implemented for high-risk children in 2002, using a 4-dose schedule, and for all children in 2004, using a 3-dose schedule. OBJECTIVES: To describe the epidemiology of hospitalized pneumonia in the population aged <5 years. METHODOLOGY: Hospital discharge records with a main diagnosis of pneumonia, pleurisy, or empyema were analyzed regarding monthly frequencies by diagnostic categories, duration of stay, proportion of cases admitted to the intensive care unit, and case fatality. RESULTS: Lobar pneumonia represented 32% of 25,319 all-cause pneumonia admissions during the period April 1997 to March 2006. Beginning in the spring of 2004, there was a marked decrease in the frequency of lobar pneumonia, whereas unspecified pneumonia tended to increase to a lesser extent. Compared with the pre-pneumococcal conjugate vaccine period, admissions for all-causes pneumonia decreased by 13% after program implementation and there was no increase in empyema cases. CONCLUSIONS: Results are reassuring as to the effectiveness of the pneumococcal vaccination program in Quebec.
BACKGROUND: In Canada, a pneumococcal conjugate vaccine was licensed in 2001, and in the province of Quebec, a publicly-funded program was implemented for high-risk children in 2002, using a 4-dose schedule, and for all children in 2004, using a 3-dose schedule. OBJECTIVES: To describe the epidemiology of hospitalized pneumonia in the population aged <5 years. METHODOLOGY: Hospital discharge records with a main diagnosis of pneumonia, pleurisy, or empyema were analyzed regarding monthly frequencies by diagnostic categories, duration of stay, proportion of cases admitted to the intensive care unit, and case fatality. RESULTS:Lobar pneumonia represented 32% of 25,319 all-cause pneumonia admissions during the period April 1997 to March 2006. Beginning in the spring of 2004, there was a marked decrease in the frequency of lobar pneumonia, whereas unspecifiedpneumonia tended to increase to a lesser extent. Compared with the pre-pneumococcal conjugate vaccine period, admissions for all-causes pneumonia decreased by 13% after program implementation and there was no increase in empyema cases. CONCLUSIONS: Results are reassuring as to the effectiveness of the pneumococcal vaccination program in Quebec.
Authors: Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel Journal: Vaccine Date: 2012-08-29 Impact factor: 3.641
Authors: Ngoc-Hang Khuc; Ben Tan; Rosalie Tuchscherer; Nigel Sb Rawson; Philippe De Wals Journal: Can J Infect Dis Med Microbiol Date: 2013 Impact factor: 2.471
Authors: Dara Lee Luca; Jeffrey C Kwong; Anna Chu; Beate Sander; Ryan O'Reilly; Allison J McGeer; David E Bloom Journal: Clin Infect Dis Date: 2018-02-01 Impact factor: 9.079